Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2006-04-04
2006-04-04
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C544S244000, C544S251000, C514S267000
Reexamination Certificate
active
07022686
ABSTRACT:
Compounds of Formula I and II are disclosed as antagonists of subtype A1 adenosine receptors. These compounds are useful for treatment of various diseases and disorders, including systemic hypertension, renal failure, diabetes, asthma, an edematous condition, congestive heart failure, and renal dysfunction.
REFERENCES:
patent: 5270316 (1993-12-01), Suzuki et al.
patent: 0 415 456 (1991-03-01), None
patent: 0 423 805 (1991-04-01), None
patent: 0 884 318 (1998-12-01), None
patent: WO 98/57651 (1998-12-01), None
patent: WO 00/01388 (2000-01-01), None
PDR Medical Dictionary p. 544 (First ed. 1995).
International Encyclopedia of Chemical Science (1964) p. 899.
M. J. Dooley et al. “Theoretical Structure-Activity Studies of Adenosine A1 Ligands: Requirements for Receptor Affinity”,Bioorg. Med. Chem., 4(6), 1996, pp. 923-934.
Lin Ko-Chung
Vu Chi
Berch Mark L.
Biogen Idec Inc.
Fish & Neave IP Group Ropes & Gray LLP
Haley, Jr. James E.
Mangasarian Karen
LandOfFree
A1 adenosine receptro antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with A1 adenosine receptro antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and A1 adenosine receptro antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3553099